Seres Therapeutics (MCRB) Financial Ratios

For fiscal 2025 (fiscal year ended Dec 31, 2025), Seres Therapeutics had a P/E ratio of 23.63 (down from 1043.26), return on equity of 19.6%, debt-to-equity of 1.88 (down from 6.65) and a current ratio of 2.56 (up from 0.94). A current ratio of 2.56 means current assets exceed current liabilities.

Seres Therapeutics Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Income Statement Balance Sheet Cash Flow Ratios

Scroll to see more

Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Valuation Ratios
P/E Ratio	23.63	1043.26	-	-	-	-
P/S Ratio	170.61	-	-	-	5.28	67.31
P/B Ratio	3.04	10.29	-4.03	64.70	5.82	12.79
Price/Tangible Book	3.04	10.29	-	64.70	5.82	12.79
Price/FCF	155.62	-	-	-	-	-
Price/OCF	120.51	-	-	-	114.40	-
Enterprise Value Ratios
EV/Revenue	218.28	-	-	-	3.18	59.60
EV/FCF	199.11	-	-	-	-	-
Profitability & Returns
Return on Equity (ROE)	19.64%	-	-	-258.04%	-42.82%	-140.99%
Return on Assets (ROA)	-42.25%	-30.42%	-34.47%	-31.96%	-11.55%	-23.17%
Return on Capital Employed (ROCE)	-79.10%	-123.10%	-75.10%	-68.40%	-23.70%	-29.70%
Leverage & Solvency Ratios
Debt/Equity	1.88	6.65	-4.43	15.08	0.37	0.23
Debt/FCF	95.91	-	-	-	-	-
Liquidity Ratios
Current Ratio	2.56	0.94	1.78	2.27	3.69	5.79
Quick Ratio	2.40	0.86	1.30	2.12	3.53	5.67
Efficiency Ratios
Asset Turnover	0.01	-	-	-	0.41	0.14
Yield & Distribution Ratios
Earnings Yield	4.23%	0.10%	-62.84%	-35.85%	-8.57%	-3.99%
FCF Yield	0.64%	-105.01%	-69.26%	-34.20%	-0.38%	-4.21%
Buyback Yield	-14.15%	-21.40%	-18.44%	-17.86%	-14.93%	-40.85%

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Seres Therapeutics Financial Ratios

What is Seres Therapeutics's P/E ratio?

Seres Therapeutics's P/E ratio was 23.63 for fiscal 2025 (period ended Dec 31, 2025). It was 1043.26 a year earlier.

What is Seres Therapeutics's return on equity?

Seres Therapeutics's return on equity (ROE) was 19.6% for fiscal 2025 (period ended Dec 31, 2025).

What is Seres Therapeutics's debt-to-equity ratio?

Seres Therapeutics's debt-to-equity ratio was 1.88 for fiscal 2025 (period ended Dec 31, 2025). It was 6.65 a year earlier.

What is return on equity (ROE)?

Return on equity is net income divided by shareholders' equity. It measures how much profit a company generates from the capital its shareholders have invested. Full definition